Login to Your Account



'Correct' CF Phase II Answer: Vertex Steps to Head of Class?

By Randy Osborne
Staff Writer

Friday, April 19, 2013
in_the_clinic.jpg

Vertex Pharmaceuticals Inc.'s approach to cystic fibrosis (CF) – pairing the approved therapy Kalydeco (ivacaftor) as a "potentiator" with another compound, VX-661, as a "corrector" – gained market-pleasing, top-line, Phase II proof that sent the stock on a skyward ride.

Shares of Cambridge, Mass.-based Vertex (NASDAQ:VRTX) closed Friday at $85.60, up $32.73, or 61.9 percent, after trading as high as $85.90.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription